menu
    • menu
    [{"orgOrder":0,"company":"Cyan Bio","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyan Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyan Bio \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cyan Bio \/ Adge Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Elocalcitol

    Menu

    Elocalcitol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cyan Bio

                            South Korea arrow
                            CPhI India
                            Not Confirmed

                            Cyan Bio

                            South Korea arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elocalcitol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Adge Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Adge Pharmaceuticals Partners with Cyan Bio of Korea to Advance Treatments for Rare Pediatric Diseases in Asia...

                            Details : Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 25, 2022

                            Lead Product(s) : Elocalcitol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Adge Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            CPhI India
                            Not Confirmed

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elocalcitol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Adge Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adge Pharmaceuticals Secures License To Evaluate Two New Programs In Rare Pediatric Diseases

                            Details : Adge Pharmaceuticals has in-licensed RO269228, a clinical stage oral small molecule, for the treatment of Rett syndrome and Osteogenesis imperfecta and potentially other indications with unmet medical needs.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : Elocalcitol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Adge Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth